Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

COSTEM 2022 | Prolymphocytes as a promising GvHD prophylaxis

Miguel-Angel Perales • 28 Oct 2022

COSTEM 2022

General Anti-thymocyte globulin

Current innovations in graft-versus-host disease (GvHD) prophylaxis include T cell depletion and administering anti-thymocyte globulin (ATG) based on lymphocyte count pre-conditioning regimen. Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the production of prolymphocytes from CD34 stem cells to prevent GvHD. Preclinical studies have demonstrated reduced rates of GvHD in patients receiving prolymphocytes. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

The utility of CD34-selected peripheral blood stem cell graft as GvHD prevention in HLA allografts

Miguel-Angel Perales • 28 Oct 2022

Transplantation and cell therapy highlights at COSTEM 2022

Miguel-Angel Perales • 28 Oct 2022

The impact of CAR-T therapy in the second-line setting in lymphoma

Miguel-Angel Perales • 28 Oct 2022

Managing CRS in CAR T-cell therapy

Miguel-Angel Perales • 5 Apr 2019

Related Videos

The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024

Natacha Bolaños • 16 Apr 2024

Distinguishing late-onset neutropenia from classical primary neutropenia

Carlo Dufour • 15 Apr 2024

The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract

James Ferrara • 16 Apr 2024

The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives

Claire Horgan • 15 Apr 2024